|Mr. Salesh Balak BA, CA||Chief Financial Officer||378.03k||N/A||49|
|Mr. Garry Chambers||VP - Technology Devel.||393.78k||N/A||54|
|Dr. Alastair McIndoe Hodges BSc. (Hons), Ph.D.||Chief Scientist||393.78k||N/A||58|
|Mr. Andrew Leslie Denver BSc (Hons), MBA, FAICD||Advisor||336.97k||N/A||69|
|Dr. Adrian Oates BSc, MSc, Ph.D.||VP - Quality & Regulatory||382.84k||N/A||57|
Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a medical diagnostics company in Australia. It focuses on the research, development, and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. The company uses electrochemical cell technology platform to develop point-of-care testing systems for various markets. Its principal products and services include Prothrombin Time International Normalized Ratio coagulation test strips; and other electrochemical-cell based tests based on enzymatic, immunoassay, and molecular diagnostic methods. Universal Biosensors, Inc. has collaboration agreement with Siemens Healthcare Diagnostics Inc. to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. The company was founded in 2001 and is based in Rowville, Australia.
Universal Biosensors, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.